Bookmark and Share Go Back Print This Page Add to Favorites
Patient Story

Successful heart surgery at We Care India partner hospital allows Robert Clarke to live a normal life despite a rare genetic disorder We Care india helped Robert find best super specialised surgeon for his rare condition.

Read More..
Video
  Types Of Cancer   Cancer Treatment   Surgeons   Cost   Location   Free Quote  

Success Rate of HIFU treatment in India


From 1995 to 1999, 559 prostate cancer patients were included in a European multi-center study. Most of the patients (n=402) were T-1 or T-2 prostate cancer patients treated with Ablatherm® HIFU as first choice therapy. In this T-1/T-2 population, negative biopsies were observed in 87.2% of the patients.

Large Cohort: European Multicentric Study 1


Hifu Treatment Success Rate,Hifu Cancer Treatment Mumbai India,HIFU, Hifu Cancer Treatment, Kidney Cancer, Bone Cancer, Blood Cancer, Cancer Therapy, Breast Surgery, Cancer Hospital In India, Medical Treatments In India, Hifu Treatment Mumbai India, Radiation Therapy, Hifu Private Patient Hospital, Hifu Treatment, High Intensity Focused Ultrasound, Haifu, Utl, Ultrasound Therapeutics

Hifu Treatment Success Rate,Hifu Cancer Treatment Mumbai India,HIFU, Hifu Cancer Treatment, Kidney Cancer, Bone Cancer, Blood Cancer, Cancer Therapy, Breast Surgery, Cancer Hospital In India, Medical Treatments In India, Hifu Treatment Mumbai India, Radiation Therapy, Hifu Private Patient Hospital, Hifu, Utl, Ultrasound Therapeutics
One important finding from these biopsy results shows that 92.1% of the low-risk patients (cancer involving less than half a lobe, PSA <10ng/ml and Gleason score lower or equal to 6) had negative biopsies during their long-term follow-up (up to 51 months).

Looking for a free cost estimate for Cancer Treatment in India abroad -click here
Or email at info@wecareindia.com / Call +91 9029304141

Long-term Results Have Been Published


A 5-year experience was reported on 146 consecutive T-1/T-2 prostate cancer patients, with a PSA level of 15 ng/ml or less. The patients were treated with Ablatherm® HIFU in the University of Regensburg, Germany, between October 1997 and November 2002.

The median PSA nadir achieved after 3 months was 0.07 ng/ml and the median PSA level after a follow-up of 22 months was 0.15 ng/ml. Also, 87% had constant PSA levels of less than 1ng/ml and 93.4% of all patients had negative control biopsies. No severe stress incontinence was observed. Erectile function was preserved in 47.3% of patients, and the International Prostate Symptom Score and Quality of Life Index did not change from before to after treatment. Studies from Lyon, France where patients were followed for more than 5 years after treatment with the Ablatherm® HIFU showed similar results.

Over 90% of patients undergoing Ablatherm® HIFU therapy will not require further treatment for their prostate cancer. In those developing a recurrence, they remain candidates for surgery, radiation or hormone therapy. Ablatherm® HIFU treatment has a similar success rate to radical prostatetomy but has the major advantage of using non-invasive technology.

If the PSA remains elevated after one treatment, however, or if a biopsy shows residual cancer of the prostate, re-treatment may be necessary. Sometimes tissue around the nerve coming into the prostate is spared on the side of the prostate gland if it has not been found by biopsy to have cancer. If a "nerve sparing" procedure is done the re-treatment rate is higher. One unique advantage of treatment with Ablatherm® HIFU is the fact that treatment is repeatable: if the nerve sparing procedure does not eliminate the cancer, the procedure can be repeated.

The results demonstrate the efficacy and low-associated morbidity of Ablatherm® HIFU. Ablatherm® HIFU seems to be a valid alternative treatment for patients who are not eligible for radical prostatectomy or who do not want to experience the potential side effects of the operation.


Failures of EBRT

Cryotherapy and Ablatherm® HIFU


In those patients developing a recurrence of their cancer after they have received external radiation, few treatment options have been available. Ablatherm® HIFU now offers a non-invasive treatment with superior results and reduces complication rates.
  Salvage HIFU% Salvage Cryotherapy%
Incontinence 35 (1) 73 (3,4)
Type 3 7 (1) 21 (3)
Obstruction 17 (1) 67 (3,5)
Impotence Information not available 85 (4)
Fistula 0 (1)
since 2002
8.7 (6)
Moderate to severe
perineal pain
less than 1% (2) 28 (4)
Success 38 (1)
30 months actuarial disease free
rate combining histologic and
biochemical results
19 (7)
35 months actuarial biochemical
disease free rate


Safety Results


The complications observed with the patients throughout European hospitals using the Ablatherm® HIFU device are quite homogeneous. The following is a chart outlining the main side effects in relation with the treatment of prostate cancer with the Ablatherm® HIFU. It is important to note that the index measuring the quality of life of the patients remains unchanged before and after the treatment.

Death 0%
Digestive complications 0%
Mild to moderate urinary incontinence 5%
Total urinary incontinence < 1%
Urethral stenosis 8%
Sexual impotence with nerve-sparing procedure 20%
Sexual impotence without nerve-sparing procedure 66%



List of HIFU Treatment's as follows : -


Do you have your medical reports; send us now for a free quote -click here
Or email at info@wecareindia.com / Call +91 9029304141



^ Back to Top

For more information, medical assessment and medical quote
send your detailed medical history and medical reports
as email attachment to
Email : - info@wecareindia.com
Call: +91 9029304141 (10 am. To 8 pm. IST)
(Only for international patients seeking treatment in India)


Only in wecareindia.com
cancer-treatment in India
 
         
         
         
  
For a detailed evaluation send patient's medical reports / X rays / doctors notes to info@wecareindia.com
 
Group Websites
Call Me Back
Cancer Treatment in India
Popular Links
We Care
  paypal money in india visa accept in india
  Paypal We accept Visa/Mater/ Amex
blank

© 2010-2011 We Care Health Services. All rights reserved.


This information is not designed to replace a physician's independent judgment about the appropriateness or risks of a procedure for a given patient.
Always consult your doctor about your medical conditions. We Care Health Services does not provide medical advice, diagnosis or treatment. Use of the wecareindia.com site is conditional upon your acceptance of our Terms and Conditions


wecareindia.com is a member of the  we care health services delhi in india medical tourism information network
blank

Home | About Us | Html Sitemap | Xml Sitemap | RSS Sitemap | Get a Quote | Disclaimer | Advertise With Us | Contact Us


Call : +91 9029304141 , US : +1 (408) 465 5252 Powered by wecareindia.com
We Care Health Services - India - Mumbai (Bombay), Chennai (Madras), Hyderabad, Kokatta, Delhi, Bangalore.
Best viewed with 1024x720